AKT1 and glioblastoma: Although our results were obtained using a single cell line and require further confirmation, they imply that in addition to the well-established role of the PI3K/Akt pathway in GBM therapy, the strategy of JNK inhibition may be employed as a tool for enhancing GBM response to therapy.